Takeda and KSQ Collaborate to Develop and Commercialize Novel Immuno-Oncology Therapies

Shots:

• KSQ to receive $100M+ as up front and preclinical milestones and up to $400M+/ program in option payment and development & commercialization milestones along with royalties on sales of each approved products
• The deal includes two KSQ’s previously identified & validated T-cell targets with the potential to introduce two additional targets to the collaboration
• Takeda will lead to funding for all development & commercialization activities. KSQ to get an option to participate in cost/profit sharing on one of the two products based on the T-cell targets previously identified and validated by KSQ, in the US and retain royalties on all ex-US sales for that product